Post hoc analysis data demonstrated pegozafermin treatment significantly reduced triglycerides and other atherogenic lipids in patients with SHTG regardless of their background lipid-modifying therapy status. These results were presented by Deepak L. Bhatt, MD, MPH, MBA, Director of Mount Sinai Heart, at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology on Saturday, March 4.
“This new analysis builds on the growing body of evidence demonstrating that treatment with pegozafermin can significantly reduce triglycerides and improve markers of atherogenic risk across a wide variety of patients with SHTG,” Dr. Bhatt said. “These findings are encouraging given the critical need for new therapeutic options that not only reduce triglyceride levels but also improve broader cardiometabolic risks for patients with SHTG regardless of their lipid-modifying treatment status.”